Pharsight

1. Drug name - INREBIC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7528143	IMPACT	Bi-aryl meta-pyrimidine inhibitors of kinases	Dec, 2026 (4 years from now)
US7825246	IMPACT	Bi-aryl meta-pyrimidine inhibitors of kinases	Dec, 2026 (4 years from now)
CN103626742B	IMPACT	Connection-Aryl-Pyrimidine Inhibitor Of Kinase	Oct, 2026 (4 years from now)
CN101370792A	IMPACT	Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases	Oct, 2026 (4 years from now)
CN103626742A	IMPACT	-Aryl Pyrimidine-Inhibitor-Linked Kinase	Oct, 2026 (4 years from now)
CN101370792B	IMPACT	-Aryl Pyrimidine-Inhibitor-Linked Kinase	Oct, 2026 (4 years from now)
IN200802704P4	IMPACT	Bi-Aryl Meta-Pyramidine Inhibitors Of Kinases	Oct, 2026 (4 years from now)
IN288239B	IMPACT	Bi-Aryl Metapyramidine Inhibitors Of Kinases	Oct, 2026 (4 years from now)
EP1951684B1	IMPACT	Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases	Oct, 2026 (4 years from now)
EP1951684A1	IMPACT	Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases	Oct, 2026 (4 years from now)
EP1951684A4	IMPACT	Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases	Oct, 2026 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199	IMPACT	Use of bi-aryl meta-pyrimidine inhibitors of kinases	Jun, 2028 (5 years from now)
US10391094	IMPACT	Compositions and methods for treating myelofibrosis	Jun, 2032 (9 years from now)

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE;ORAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.